Regeneron Pharmaceuticals, Inc. and Lantheus Holdings, Inc.: A Detailed Gross Profit Analysis

Regeneron vs. Lantheus: A Decade of Financial Growth

__timestampLantheus Holdings, Inc.Regeneron Pharmaceuticals, Inc.
Wednesday, January 1, 20141255190002614539000
Thursday, January 1, 20151355220003711019000
Friday, January 1, 20161377800004560733000
Sunday, January 1, 20171621350005475166000
Monday, January 1, 20181748850006276700000
Tuesday, January 1, 20191748110007081200000
Wednesday, January 1, 20201387610007377200000
Friday, January 1, 202118769500013634200000
Saturday, January 1, 202258170300010612500000
Sunday, January 1, 202370954300011301400000
Monday, January 1, 202412231500000
Loading chart...

Unveiling the hidden dimensions of data

A Decade of Growth: Regeneron vs. Lantheus

In the ever-evolving landscape of pharmaceuticals, the financial trajectories of Regeneron Pharmaceuticals, Inc. and Lantheus Holdings, Inc. offer a compelling narrative of growth and innovation. Over the past decade, Regeneron has consistently outperformed Lantheus in terms of gross profit, showcasing a robust growth trajectory. From 2014 to 2023, Regeneron's gross profit surged by approximately 332%, peaking in 2021 with a remarkable 13.6 billion dollars. In contrast, Lantheus, while smaller in scale, demonstrated a significant upward trend, with a 465% increase in gross profit over the same period, reaching its zenith in 2023.

This analysis highlights the dynamic nature of the pharmaceutical industry, where strategic innovation and market adaptation are key. As we delve into these financial insights, it becomes evident that both companies are poised for continued success, albeit on different scales.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025